Ipsen's new corabotase shows rapid results in wrinkle treatment study

Pharmaceutical company Ipsen announced late-breaking Phase II data for corabotase, a first-in-class treatment for glabellar lines showing rapid onset of action within 0.84 days. At week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration compared to placebo and Dysport, with patient satisfaction reaching 82.8%.